Fresh Tracks Therapeutics, Inc. (FRTX)
OTCMKTS: FRTX · Delayed Price · USD
0.930
+0.020 (2.20%)
Apr 24, 2024, 1:05 PM EDT - Market closed
Company Description
Fresh Tracks Therapeutics, Inc. does not have significant operations.
Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.
Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Tracks Therapeutics, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Albert Nicholas Marchio II |
Contact Details
Address: 2000 Central Avenue, Suite 100 Boulder, Colorado 80301 United States | |
| Phone | (720) 505-4755 |
| Website | frtx.com |
Stock Details
| Ticker Symbol | FRTX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000819050 |
| ISIN Number | AU000000ELD6 |
| Employer ID | 93-0948554 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Albert Nicholas Marchio II | Chief Executive Officer, Chief Financial Officer, Secretary and Chairman |
| Aron Aizenstat M.B.A., P.M.P. | Vice President of Corporate Development and Operations |
| Aaron Fox-Collis CPA | Vice President of Finance and Chief Accounting Officer |
| Sue Fattor | Head of Human Resource |
| Dr. James S. McElvain Ph.D. | Interim Head of CMC Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2024 | 15-12G | Securities registration termination |
| Mar 15, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 17, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Jan 3, 2024 | 8-K | Current Report |